Tagomics is aiming to improve drug safety monitoring with a new cell-free DNA blood test built on its LiquiPath platform. The company’s approach uses tagging and enrichment of unmethylated genomic regions to monitor multiple organs for toxicity signals. The platform reflects growing interest in multiplex pharmacovigilance tools that can detect adverse effects earlier than conventional organ-specific biomarkers. Tagomics positions the assay as a systems-level readout for therapy-induced injury. —